Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
20
TNYA Quote, Financials, Valuation and Earnings
Last price:
$0.72
Seasonality move
:
-1.73%
Day range:
$0.70 - $0.75
52-week range:
$0.36 - $2.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.52x
Volume:
2.3M
Avg. volume:
5.7M
1-year change:
-53.16%
Market cap:
$125.6M
Revenue:
--
EPS (TTM):
-$0.79
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TNYA
Tenaya Therapeutics, Inc.
|
-- | -$0.15 | -- | -53.79% | $9.43 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
APLT
Applied Therapeutics, Inc.
|
$250K | -$0.14 | 104.92% | -70.54% | $0.25 |
|
BEAT
HeartBeam, Inc.
|
-- | -- | -- | -- | $4.63 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$383K | -$0.02 | -24.9% | -15.25% | $3.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TNYA
Tenaya Therapeutics, Inc.
|
$0.75 | $9.43 | $125.6M | -- | $0.00 | 0% | -- |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
APLT
Applied Therapeutics, Inc.
|
$0.11 | $0.25 | $15.2M | -- | $0.00 | 0% | 14.95x |
|
BEAT
HeartBeam, Inc.
|
$2.49 | $4.63 | $85.8M | -- | $0.00 | 0% | -- |
|
CVM
CEL-SCI Corp.
|
$5.19 | $42.50 | $15.7M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.30 | $3.88 | $27.9M | -- | $0.00 | 0% | 22.51x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TNYA
Tenaya Therapeutics, Inc.
|
12.21% | 6.423 | 4.35% | 4.26x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
APLT
Applied Therapeutics, Inc.
|
128.93% | 3.416 | 2.86% | 0.36x |
|
BEAT
HeartBeam, Inc.
|
-- | 1.449 | -- | 0.75x |
|
CVM
CEL-SCI Corp.
|
37.03% | 1.679 | 33.61% | 2.14x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.805 | 0.39% | 0.78x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TNYA
Tenaya Therapeutics, Inc.
|
-$1.9M | -$20.9M | -82.34% | -92.86% | -- | -$15.6M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
APLT
Applied Therapeutics, Inc.
|
$889K | -$16.8M | -70.3% | -77.88% | -1675.8% | -$18.4M |
|
BEAT
HeartBeam, Inc.
|
-$8K | -$5.3M | -555.14% | -555.14% | -- | -$3.2M |
|
CVM
CEL-SCI Corp.
|
-$960.8K | -$6M | -117.93% | -230.36% | -- | -$4.7M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
Tenaya Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns TNYA or AIM?
AIM ImmunoTech has a net margin of -- compared to Tenaya Therapeutics, Inc.'s net margin of -10571.43%. Tenaya Therapeutics, Inc.'s return on equity of -92.86% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital TNYATenaya Therapeutics, Inc.-- -$0.12 $94.4M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About TNYA or AIM?
Tenaya Therapeutics, Inc. has a consensus price target of $9.43, signalling upside risk potential of 1150.31%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Tenaya Therapeutics, Inc., analysts believe AIM ImmunoTech is more attractive than Tenaya Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TNYATenaya Therapeutics, Inc.6 0 0 AIMAIM ImmunoTech1 0 0 -
Is TNYA or AIM More Risky?
Tenaya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock TNYA or AIM?
Tenaya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tenaya Therapeutics, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNYA or AIM?
Tenaya Therapeutics, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Tenaya Therapeutics, Inc.'s net income of -$20.3M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Tenaya Therapeutics, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tenaya Therapeutics, Inc. is -- versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNYATenaya Therapeutics, Inc.-- -- -- -$20.3M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns TNYA or APLT?
Applied Therapeutics, Inc. has a net margin of -- compared to Tenaya Therapeutics, Inc.'s net margin of -1899%. Tenaya Therapeutics, Inc.'s return on equity of -92.86% beat Applied Therapeutics, Inc.'s return on equity of -77.88%.
Company Gross Margin Earnings Per Share Invested Capital TNYATenaya Therapeutics, Inc.-- -$0.12 $94.4M APLTApplied Therapeutics, Inc.88.9% -$0.13 $1.9M -
What do Analysts Say About TNYA or APLT?
Tenaya Therapeutics, Inc. has a consensus price target of $9.43, signalling upside risk potential of 1150.31%. On the other hand Applied Therapeutics, Inc. has an analysts' consensus of $0.25 which suggests that it could grow by 138.1%. Given that Tenaya Therapeutics, Inc. has higher upside potential than Applied Therapeutics, Inc., analysts believe Tenaya Therapeutics, Inc. is more attractive than Applied Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TNYATenaya Therapeutics, Inc.6 0 0 APLTApplied Therapeutics, Inc.0 4 0 -
Is TNYA or APLT More Risky?
Tenaya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Applied Therapeutics, Inc. has a beta of 1.989, suggesting its more volatile than the S&P 500 by 98.936%.
-
Which is a Better Dividend Stock TNYA or APLT?
Tenaya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tenaya Therapeutics, Inc. pays -- of its earnings as a dividend. Applied Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNYA or APLT?
Tenaya Therapeutics, Inc. quarterly revenues are --, which are smaller than Applied Therapeutics, Inc. quarterly revenues of $1M. Tenaya Therapeutics, Inc.'s net income of -$20.3M is lower than Applied Therapeutics, Inc.'s net income of -$19M. Notably, Tenaya Therapeutics, Inc.'s price-to-earnings ratio is -- while Applied Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tenaya Therapeutics, Inc. is -- versus 14.95x for Applied Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNYATenaya Therapeutics, Inc.-- -- -- -$20.3M APLTApplied Therapeutics, Inc.14.95x -- $1M -$19M
-
Which has Higher Returns TNYA or BEAT?
HeartBeam, Inc. has a net margin of -- compared to Tenaya Therapeutics, Inc.'s net margin of --. Tenaya Therapeutics, Inc.'s return on equity of -92.86% beat HeartBeam, Inc.'s return on equity of -555.14%.
Company Gross Margin Earnings Per Share Invested Capital TNYATenaya Therapeutics, Inc.-- -$0.12 $94.4M BEATHeartBeam, Inc.-- -$0.15 $406K -
What do Analysts Say About TNYA or BEAT?
Tenaya Therapeutics, Inc. has a consensus price target of $9.43, signalling upside risk potential of 1150.31%. On the other hand HeartBeam, Inc. has an analysts' consensus of $4.63 which suggests that it could grow by 85.74%. Given that Tenaya Therapeutics, Inc. has higher upside potential than HeartBeam, Inc., analysts believe Tenaya Therapeutics, Inc. is more attractive than HeartBeam, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TNYATenaya Therapeutics, Inc.6 0 0 BEATHeartBeam, Inc.2 1 0 -
Is TNYA or BEAT More Risky?
Tenaya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HeartBeam, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock TNYA or BEAT?
Tenaya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HeartBeam, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tenaya Therapeutics, Inc. pays -- of its earnings as a dividend. HeartBeam, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNYA or BEAT?
Tenaya Therapeutics, Inc. quarterly revenues are --, which are smaller than HeartBeam, Inc. quarterly revenues of --. Tenaya Therapeutics, Inc.'s net income of -$20.3M is lower than HeartBeam, Inc.'s net income of -$5.3M. Notably, Tenaya Therapeutics, Inc.'s price-to-earnings ratio is -- while HeartBeam, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tenaya Therapeutics, Inc. is -- versus -- for HeartBeam, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNYATenaya Therapeutics, Inc.-- -- -- -$20.3M BEATHeartBeam, Inc.-- -- -- -$5.3M
-
Which has Higher Returns TNYA or CVM?
CEL-SCI Corp. has a net margin of -- compared to Tenaya Therapeutics, Inc.'s net margin of --. Tenaya Therapeutics, Inc.'s return on equity of -92.86% beat CEL-SCI Corp.'s return on equity of -230.36%.
Company Gross Margin Earnings Per Share Invested Capital TNYATenaya Therapeutics, Inc.-- -$0.12 $94.4M CVMCEL-SCI Corp.-- -$0.76 $25.3M -
What do Analysts Say About TNYA or CVM?
Tenaya Therapeutics, Inc. has a consensus price target of $9.43, signalling upside risk potential of 1150.31%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 718.88%. Given that Tenaya Therapeutics, Inc. has higher upside potential than CEL-SCI Corp., analysts believe Tenaya Therapeutics, Inc. is more attractive than CEL-SCI Corp..
Company Buy Ratings Hold Ratings Sell Ratings TNYATenaya Therapeutics, Inc.6 0 0 CVMCEL-SCI Corp.1 0 0 -
Is TNYA or CVM More Risky?
Tenaya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock TNYA or CVM?
Tenaya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tenaya Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNYA or CVM?
Tenaya Therapeutics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Tenaya Therapeutics, Inc.'s net income of -$20.3M is lower than CEL-SCI Corp.'s net income of -$6.1M. Notably, Tenaya Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tenaya Therapeutics, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNYATenaya Therapeutics, Inc.-- -- -- -$20.3M CVMCEL-SCI Corp.-- -- -- -$6.1M
-
Which has Higher Returns TNYA or IGC?
IGC Pharma, Inc. has a net margin of -- compared to Tenaya Therapeutics, Inc.'s net margin of -953.4%. Tenaya Therapeutics, Inc.'s return on equity of -92.86% beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital TNYATenaya Therapeutics, Inc.-- -$0.12 $94.4M IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About TNYA or IGC?
Tenaya Therapeutics, Inc. has a consensus price target of $9.43, signalling upside risk potential of 1150.31%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1192.1%. Given that IGC Pharma, Inc. has higher upside potential than Tenaya Therapeutics, Inc., analysts believe IGC Pharma, Inc. is more attractive than Tenaya Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TNYATenaya Therapeutics, Inc.6 0 0 IGCIGC Pharma, Inc.2 0 0 -
Is TNYA or IGC More Risky?
Tenaya Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.
-
Which is a Better Dividend Stock TNYA or IGC?
Tenaya Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tenaya Therapeutics, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TNYA or IGC?
Tenaya Therapeutics, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Tenaya Therapeutics, Inc.'s net income of -$20.3M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Tenaya Therapeutics, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tenaya Therapeutics, Inc. is -- versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TNYATenaya Therapeutics, Inc.-- -- -- -$20.3M IGCIGC Pharma, Inc.22.51x -- $191K -$1.8M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
89
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 18.81% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Buy
72
GLTO alert for Dec 30
Galecto, Inc. [GLTO] is down 12.13% over the past day.
